MONMOUTH JUNCTION, N.J.,
April 27, 2021 /PRNewswire/
-- CytoSorbents Corporation (NASDAQ: CTSO), a critical
care immunotherapy leader commercializing its CytoSorb® blood
purification technology to treat deadly inflammation in
critically-ill and cardiac surgery patients around the
world, will report Q1 2021 financial results after the market
close on Tuesday, May 4, 2021 at
4:45PM EST.
CytoSorbents Corporation to Report Q1 2021 Operating and Financial
Results on Tuesday, May 4, 2021
CytoSorbents' management will host a live conference call and
presentation webcast that will recount both operational and
financial progress during Q1 2021 followed by a question and answer
session.
Conference Call Details:
Date:
|
Tuesday, May 4,
2021
|
Time:
|
4:45 PM
Eastern
|
Toll Free:
|
877-451-6152
|
International:
|
201-389-0879
|
Conference
ID:
|
13718834
|
Live Presentation
Webcast:
|
http://public.viavid.com/index.php?id=144427
|
It is recommended that participants dial in approximately 10
minutes prior to the start of the call. There will also be a
simultaneous live webcast of the conference call that can be
accessed through the following audio feed link:
http://public.viavid.com/index.php?id=144427
An archived recording of the conference call will be available
under the Investor Relations section of the Company's website at
http://cytosorbents.com/investor-relations/financial-results/
About CytoSorbents Corporation
(NASDAQ: CTSO)
CytoSorbents Corporation is a leader in critical care
immunotherapy, specializing in blood purification. Its flagship
product, CytoSorb® is approved in the European Union with
distribution in 67 countries around the world, as an
extracorporeal cytokine adsorber designed to reduce the "cytokine
storm" or "cytokine release syndrome" that could otherwise cause
massive inflammation, organ failure and death in common critical
illnesses. These are conditions where the risk of death is
extremely high, yet no effective treatments
exist. CytoSorb® is also being used during and
after cardiac surgery to remove inflammatory mediators that can
lead to post-operative complications, including multiple organ
failure. CytoSorb® has been used in more than
121,000 human treatments to date. CytoSorb has received CE-Mark
label expansions for the removal of bilirubin (liver disease),
myoglobin (trauma), and
both ticagrelor and rivaroxaban during
cardiothoracic surgery. CytoSorb has also received FDA
Emergency Use Authorization in the United States for
use in critically ill COVID-19 patients with imminent or confirmed
respiratory failure, in defined circumstances. CytoSorb has
also been granted FDA Breakthrough Designation for the
removal of ticagrelor in a cardiopulmonary bypass circuit during
emergent and urgent cardiothoracic surgery.
CytoSorbents' purification technologies are based on
biocompatible, highly porous polymer beads that can actively remove
toxic substances from blood and other bodily fluids by pore capture
and surface adsorption. Its technologies have received non-dilutive
grant, contract, and other funding of more than $38
million from DARPA, the U.S. Department of Health and Human
Services (HHS), the National Institutes of Health (NIH), National
Heart, Lung, and Blood Institute (NHLBI), the U.S. Army, the U.S.
Air Force, U.S. Special Operations Command (SOCOM), Air Force
Material Command (USAF/AFMC), and others. The Company has numerous
products under development based upon this unique blood
purification technology protected by many issued U.S. and
international patents and multiple applications pending, including
ECOS-300CY™, CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™,
VetResQ™, K+ontrol™, DrugSorb™, ContrastSorb, and
others. For more information, please visit the Company's
websites at www.cytosorbents.com and www.cytosorb.com or follow us
on Facebook and Twitter.
Forward-Looking Statements
This press release includes forward-looking statements intended
to qualify for the safe harbor from liability established by the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, but are not limited to,
statements about our plans, objectives, representations and
contentions and are not historical facts and typically are
identified by use of terms such as "may," "should," "could,"
"expect," "plan," "anticipate," "believe," "estimate," "predict,"
"potential," "continue" and similar words, although some
forward-looking statements are expressed differently. You should be
aware that the forward-looking statements in this press release
represent management's current judgment and expectations, but our
actual results, events and performance could differ materially from
those in the forward-looking statements. Factors which could cause
or contribute to such differences include, but are not limited to,
our ability to leverage designation of CytoSorb as a breakthrough
device under the FDA's Breakthrough Devices Program in order
to expedite the development, assessment, and regulatory review of
CytoSorb, as well as the risks discussed in our Annual Report on
Form 10-K, filed with the SEC on March 9, 2021, as updated by
the risks reported in our Quarterly Reports on Form 10-Q, and
Current Reports on Form 8-K, and in the press releases and other
communications to shareholders issued by us from time to time which
attempt to advise interested parties of the risks and factors which
may affect our business. We caution you not to place undue reliance
upon any such forward-looking statements, particularly in light of
the current coronavirus pandemic, where businesses can be impacted
by rapidly changing state and federal regulations, as well as the
health and availability of their workforce. We undertake no
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events,
or otherwise, other than as required under the Federal securities
laws.
Please Click to Follow Us on Facebook and Twitter
CytoSorbents Contact:
Amy Vogel
(732) 398-5394
avogel@cytosorbents.com
Public Relations Contact:
Eric Kim
Rubenstein Public Relations
212-805-3052
ekim@rubensteinpr.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/cytosorbents-to-report-q1-2021-operating-and-financial-results-301278274.html
SOURCE CytoSorbents Corporation